Cliff Asness’s SpringWorks Therapeutics SWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-96,027
Closed -$4.51M 3588
2025
Q2
$4.51M Buy
96,027
+31,291
+48% +$1.39M ﹤0.01% 1344
2025
Q1
$2.86M Buy
64,736
+43,855
+210% +$2.02M ﹤0.01% 1413
2024
Q4
$754K Sell
20,881
-23,075
-52% -$806K ﹤0.01% 2045
2024
Q3
$1.41M Buy
43,956
+6,543
+17% +$244K ﹤0.01% 1674
2024
Q2
$1.41M Buy
37,413
+18,017
+93% +$758K ﹤0.01% 1609
2024
Q1
$955K Buy
+19,396
New +$897K ﹤0.01% 1714
2021
Q4
Sell
-7,258
Closed -$460K 2276
2021
Q3
$460K Buy
7,258
+1,761
+32% +$136K ﹤0.01% 1894
2021
Q2
$453K Buy
5,497
+1,455
+36% +$110K ﹤0.01% 1936
2021
Q1
$297K Buy
+4,042
New +$317K ﹤0.01% 2010

Other funds holding SWTX

Cliff Asness's SWTX Position: Q3 2025 in Review

Cliff Asness sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 96,027 shares — an estimated $4.51M sold.

Cliff Asness first reported a position in SWTX in Q1 2021 and held it in 9 quarters. The position peaked at $4.51M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

  • Cliff Asness reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cliff Asness sold 96,027 SpringWorks Therapeutics shares in Q3 2025, an estimated $4.51M.
  • Cliff Asness first reported a position in SpringWorks Therapeutics in Q1 2021 and held it in 9 quarters.
  • Cliff Asness's SpringWorks Therapeutics position peaked at $4.51M in Q2 2025.
  • 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on AQR Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.